TRML VS NVS Stock Comparison

Performance

TRML
100/100

TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

NVS
100/100

NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.

Volatility

TRML
67/100

TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

NVS
44/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

TRML

"Analyst Price Targets" not found for TRML

NVS
67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.

Technicals

TRML

"Technicals" not found for TRML

NVS
10/100

NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

TRML

"Earnings" not found for TRML

NVS
39/100

NVS has missed earnings 5 times in the last 20 quarters.

Profit

TRML

"Profit" not found for TRML

NVS
73/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

All score calculations are broken down here to help you make more informed investing decisions

Tourmaline Bio, Inc. Common Stock Summary

Nasdaq / TRML

Healthcare

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Novartis AG Summary

New York Stock Exchange / NVS

Healthcare

Drug Manufacturers - General

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Power up your portfolio